Mostrando entradas con la etiqueta DIABETES MELLITUS. Mostrar todas las entradas
Mostrando entradas con la etiqueta DIABETES MELLITUS. Mostrar todas las entradas

viernes, 12 de junio de 2015

Experts reflect on the past, present and future of diabetes

Over r the past 50 years, treatment and outcomes for diabetes have changed dramatically. At a recent symposium, experts looked back at how lives have changed over the past 5 decades and what remains to be addressed over the next 5.

The symposium was held at the American Diabetes Association's (ADA) 75th Scientific Sessions.
"There are things that have happened over the past 50 years that clearly make life a lot better for people," says Dr. Fred Whitehouse, of the Henry Ford Health System in Detroit, MI. "There's been a lot of change, most of it for the better, but what people want is a cure and we don't have that yet."
Dr. Whitehouse has overseen many changes in how people with diabetes have been treated. When he first started treating people with the condition, the only form of treatment was the injection of animal insulin, obtained from cows or pigs, which could sometimes cause adverse reactions.
Nowadays, human insulin is used, produced by microorganisms and delivered through a variety of different systems including insulin pumps. There are now fewer adverse reactions and no fear of supplies running out, Dr. Whitehouse says, with methods of delivery that are more accurate than ever before.
Glucose levels can also be tracked more accurately. Previously, diabetes control could only be assessed by analyzing the levels of sugar in urine. There are many more options available to patients now, including the noninvasive A1C test that measures average levels over 3 months, "showing whether a person is on the right road or not," states Dr. Whitehouse.
As methods for treating and tracking the disorder have improved for patients, so too has the collective understanding of diabetes shared by researchers and clinicians. It takes a long time for research to make a clinical impact and recent years have seen the results of 50 years of hard work.
Dr. Daniel Porte, Jr., a professor at the University of California-San Diego, describes one of the most recent discoveries in the field:
"This year, amazingly enough to me, it was discovered that insulin sent to the central nervous system not only feeds back to the brain, it also affects glucose production. It regulates the islet cells, so there is a complete integration of the endocrine system and the nervous system. It took 40 years to discover this."
Originally, the endocrine and nervous systems were believed to function completely independently of each other, with glucose the sole regular of insulin.

In 50 years, 'complications of diabetes should become historical memories'

Dr. Porte states that with diabetes research, it is crucial to be patient. "For example, the drugs we use now to treat diabetes were first studied 30 to 40 years ago. And there are many more than the one or two that were being used back in the 1970s."
Such research not only leads to an improved understanding of diabetes but of other conditions as well. "We now believe that perhaps impaired insulin action in the central nervous system leads to the behavioral changes we see in Alzheimer's patients," Dr. Porte explains.
Dr. Michael Brownlee, associate director for biomedical sciences at the Albert Einstein College of Medicine's Diabetes Research Center in New York City, NY, states that diabetes is such a serious health problem due to its complications. His research on the mechanisms that cause complications such as eye and kidney disease has led to great change.
"Prior to the Diabetes Control and Complications Trial (DCCT) study that was published [in 1993], the general dogma was that diabetes caused both metabolic changes and complications, which had nothing to do with each other. They were just two parallel manifestations of the disease," he says.
"Now it's known that prolonged high glucose levels increase the risk for eye and kidney complications associated with diabetes, and maintaining tighter control of blood glucose levels reduces that risk."
Although the landscape of diabetes treatment and research has changed radically over the past 50 years, physicians are still only able to manage the disease rather than cure it. Dr. Robert Ratner, chief scientific & medical officer for the ADA, outlines what needs to be done:
"The next 50 years must elucidate the mechanisms by which both type 1 and type 2 diabetes occur, along with those critical steps at which we might intervene to prevent disease. Treatments must provide optimal glucose and metabolic control, without the risk of hypoglycemia, and complications of diabetes should become historical memories."
If research and treatment can progress at the same rate over the next 5 decades as it has over the past 5, who is to say what can be accomplished?
Tomado de McIntosh, J. (2015, June 8). "Experts reflect on the past, present and future of diabetes." Medical News Today. Retrieved from
.

sábado, 4 de octubre de 2014

New study challenges claims that low vitamin D causes type 2 diabetes

A new study from the University of Cambridge in the UK challenges findings of earlier research that concludes having higher levels of circulating vitamin D might prevent type 2 diabetes.
These earlier observational studies raised suggestions that low vitamin D contributes to the development of type 2diabetes. But because they were not designed to investigate cause and effect, they could not prove it: they could only establish a link.
Now a large genetic study published in The Lancet Diabetes and Endocrinology journal, concludes there is no evidence that a person's low level of vitamin D leads them to develop type 2 diabetes.
Senior author Dr. Nita Forouhi, leader of the Nutritional Epidemiology program at Cambridge's Medical Research Council (MRC) Epidemiology Unit, says:
"Observational studies that show a strong and consistent higher risk of type 2 diabetes with lower levels of vitamin D may do so because they have thus far not been able to adequately control for distorting or confounding factors, such as physical activity levels, that may be related both to vitamin D levels and to the risk of type 2 diabetes."
Using data from several studies covering thousands of people of European descent, Dr. Forouhi and colleagues investigated the link between levels of vitamin D and risk of developing diabetes by examining the genes that control blood levels of vitamin D.
The authors also used circulating 25-hydroxyvitamin D levels - considered the best indicator of vitamin D status - as the measure for vitamin D. Insufficiency was defined as having blood levels of 25-hydroxyvitamin D under 50 nmol/L.

No evidence that low vitamin D causes type 2 diabetes

The researchers found no evidence of a link between the risk of developing type 2 diabetes and the different gene variants that control blood levels of vitamin D.
They also found no links between varying levels of vitamin D and several features of type 2 diabetes, such as glucose and glycated hemoglobin, and neither did they find evidence that low vitamin D causes the disease.
Dr. Forouhi says their results echo those of randomized controlled trials - the classic way to test cause and effect links - which have generally concluded taking vitamin D supplements does not stop people developing type 2 diabetes.
"Our findings suggest that interventions to reduce the risk of type 2 diabetes by increasing concentrations of vitamin D are not currently justified," she notes.

Research must continue, especially with longer-term trials say experts

However, "we are far from done with this topic," says Dr. Forouhi who calls for better clinical trials and observational studies to measure more precisely the factors that might link vitamin D to disease.
"Until then, we need to be cautious about vitamin D's potential role in the prevention of type 2 diabetes and stick to things that are proven to work - diet and exercise," she urges.
One of the reasons to persist with research on the link between vitamin D and diabetes is that there appears to be a plausible biological explanation. The active form of the vitamin interacts with proteins in the insulin-producing beta cells in the pancreas. Also, people with diabetes tend to have low blood levels of vitamin D.
Another expert commenting in a linked article says the new findings need to be interpreted carefully. He also makes the point that despite the fact results of short-term studies do not appear to offer much hope, we need to await the results of longer-term trials before drawing final conclusions. However:
"The sky is becoming rather clouded for vitamin D in the context of preventing type 2 diabetes," says Dr. Brian Buijsse, of the German Institute of Human Nutrition in Potsdam-Rehbruecke in Germany.
This news follows reports of another UK study that found contrary to some previous claims, taking vitamin D supplements does not prevent heart attack or stroke.
Tomado: Medical News Today  Written by Catharine Paddock PhD.    Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study, Zheng Ye, et al., Lancet Diabetes Endocrinol, DOI: 10.1016/S2213-8587(14)70184-6, abstract.

miércoles, 1 de octubre de 2014

Gene Study Finds No Proof Vitamin D Guards Against Type 2 Diabetes

There's no genetic evidence that high levels of vitamin D can prevent type 2 diabetes, a new study says.
Some previous research had suggested that elevated levels of vitamin D might protect people against type 2 diabetes, raising the possibility of a link between vitamin D deficiency and the blood sugar disease.
In this study, British researchers investigated the association between diabetes risk and vitamin D by focusing on genes that control blood levels of vitamin D. They found no connection between different variants of these genes and the risk of developing type 2 diabetes.
The results were published Sept. 30 in The Lancet Diabetes & Endocrinology.
"Our findings suggest that interventions to reduce the risk of type 2 diabetes by increasing concentrations of vitamin D are not currently justified. Observational studies that show a strong and consistent higher risk of type 2 diabetes with lower levels of vitamin D may do so because they have thus far not been able to adequately control for distorting or confounding factors, such as physical activity levels," study author Dr. Nita Forouhi, of the University of Cambridge's School of Clinical Medicine, said in a journal news release.
The findings add to evidence showing that taking vitamin D supplements does not prevent diabetes. The only proven ways to prevent type 2 diabetes are diet and exercise, Forouhi said.
One expert noted that long-term trials that are still looking at any possible connection should be weighed in the final analysis.
The results "need careful interpretation, and long-term randomized trials of vitamin D supplementation, which are underway, remain important," Dr. Brian Buijsse, from the German Institute of Human Nutrition Potsdam-Rehbruecke in Germany, wrote in an accompanying commentary in the journal.
"The results of an [analysis] of 35 short-term trials, however, do not offer much hope that vitamin D supplementation can be used to prevent type 2 diabetes. The sky is becoming rather clouded for vitamin D in the context of preventing type 2 diabetes," he said.
Tomado de : Healthday.com
SOURCE: The Lancet Diabetes & Endocrinology, news release, Sept. 30, 2014

miércoles, 17 de septiembre de 2014

Cortical bone microstructure, tibia density deficits seen with type 2 diabetes, high HbA1c

Type 2 diabetes and increased HbA1c are associated with deficits in cortical bone microstructure and bone density at the distal tibia, according to research presented at the American Society for Bone and Mineral Research 2014 Annual Meeting
Although it is still uncertain whether the cortical bone deficits explain increased lower leg fracture risks seen in patients with diabetes, the findings identify target areas to investigate the mechanism responsible for skeletal fragility.
“Diabetic bone may be characterized by specific deficits to cortical bone, which are not captured by traditional DXA bone mineral density tests,” Elizabeth J. Samelson, PhD, of the Institute for Aging Research at Hebrew SeniorLife, Harvard Medical School,
amelson and colleagues conducted a community-based study involving 627 adults (367 women, 260 men; mean age, 65 years) to compare bone microarchitecture by high-resolution peripheral quantitative computed tomography (HRpQCT) in patients with type 2 diabetes (31 women, 40 men) and healthy individuals and determine relationships with HbA1c.
Participants, all from the Framingham Offspring Cohort, were evaluated for type 2 diabetes and had HbA1c measured at baseline; diabetes was defined as glucose >126 mg/dl or use of diabetes medication. They all underwent HRpQCT scanning at the tibia and radius at 6 years.
The researchers used linear regression to calculate means and correlations for the association between volumetric bone mineral density (vBMD), geometry and microstructure indices of trabecular and cortical bone and type 2 diabetes and HbA1C. Adjustments were made for age, sex and weight. 
Patients with type 2 diabetes exhibited higher numbers than healthy patients at the tibia for
total vBMD (291.06 mg/cm3 vs. 284 .53 mg/ cm3), trabecular vBMD (184.13 mg/cm3 vs. 175.09 mg/cm3) and trabecular number (2.15 1/mm vs. 2.07 1/mm); the differences were not significant.
Conversely, patients with type 2 diabetes demonstrated significantly lower numbers than healthy patients for cortical vBMD (796.74 mg/cm3 vs. 814 mg/cm3) and cortical porosity (11.17% vs. 10.03%).
Similar results were seen with increasing HbA1c, with trabecular indices better with higher levels but cortical bone indices worse; the significance was limited to trabecular number.
No other differences were seen in HRpQCT bone indices between groups or based on HbA1c level. At the radius, no significant associations were seen between bone HRpQCT indices and type 2 diabetes or HbA1C.
“Older adults with type 2 diabetes have increased risk of fracture but higher bone mass density than those without diabetes,” Samelson said. “ If deficits to cortical bone explain increased skeletal fragility in type 2 diabetes, then future therapies that target cortical bone strength can reduce fracture risk in this vulnerable and growing population.” — by Allegra Tiver
For more information: Samelson E. Abstract 1083. Presented at: American Society for Bone and Mineral Research 2014 Annual Meeting; Sept. 12-15, 2014; Houston.
Tomado de http://www.healio.com/endocrinology/bone-mineral-metabolism

martes, 9 de septiembre de 2014

Inflammatory marker signals diabetic nephropathy development

Measuring serum levels of high-sensitivity C-reactive protein (hs-CRP) could help to predict which patients with Type 2 diabetes will develop renal disease, research suggests.

Results of a prospective cohort study conducted in Japan show that patients with the highest hs-CRP levels were more likely to develop microalbuminuria than those with the lowest levels.
Over a median follow-up of 0.94 years, 197 patients developed diabetic nephropathy, with an incidence ratio of 155.4 per 1000 person–years. Adjusted hazard ratios (HR) for the risk of developing nephropathy associated with the second, third and fourth hs-CRP quartiles versus the first quartile were 1.31, 1.55 and 1.57, respectively.
However, hs-CRP levels did not appear to be associated with the progression from microalbuminuria to macroalbuminuria. During the same follow-up period, 109 patients experienced diabetic nephropathy progression, with an incidence ratio of 92.4 per 1000 patient–years. Adjusted HRs were 0.59, 1.14 and 1.03, respectively, for the lowest versus the second, third and fourth highest quartiles of hs-CRP, respectively.
“Our study identifies new information regarding CRP and disease outcomes”, observe Yasuaki Hayashino, from Tenri Hospital in Nara, Japan, and co-authors.
“There is a temporal association between elevated levels of hs-CRP and the subsequent risk of developing, not progressing, diabetic nephropathy”, they write in Diabetes Care, adding that this association is seen “even after adjusting for possible confounders, including medication use which may influence the natural course of renal function.”
Longitudinal data on 2518 patients with Type 2 diabetes were obtained from the Diabetes Distress and Care Registry at Tenri study to look at the association between baseline hs-CRP and subsequent risk of development or progression of diabetic nephropathy at 1 year.
Development of diabetic nephropathy was defined as the transition from normoalbuminuria (urinary albumin-to-creatinine ratio [UACR]  menor 3.4 mg/mmol) to microalbuminuria (UACR 3.4–33.9 mg/mmol), and progression as the transition from microalbuminuria to macroalbuminuria (UACR mayor o igual a33.9 mg/mmol).

Hayashino et al note that their results were obtained from studying patients seen at a single diabetes centre in Japan, and so it remains to be seen if they apply to multi-ethnic populations in North American and Europe.
“More research is needed to examine if there is an effective strategy to reduce the risk of diabetic nephropathy in a group of patients with diabetes and elevated levels of hs-CRP”, they conclude.

Tomado de:medwireNews (www.medwirenews.com

lunes, 11 de agosto de 2014

Vegan Diet Eases Diabetic Neuropathy Pain

A plant-based diet may help relieve diabetic nerve pain, according to a randomized trial presented here.
In the 15-patient DINE study, patients with type 2 diabetes and diabetic neuropathy who were randomized to a vegan diet and B12 supplementation had greater improvement in pain scores than those who only took the vitamin, according to Anne Bunner, PhD, and Caroline Trapp, MSN, of the Physicians Committee for Responsible Medicine.
They reported their findings at theAmerican Association of Diabetes Educators meeting here. "Diabetic peripheral neuropathy is underdiagnosed, partially because there's not a whole lot for physicians to offer these patients," Bunner said. "We wanted to know if in the setting of a randomized controlled trial a low-fat vegan diet can make a difference in diabetic neuropathy pain."
Bunner noted that current treatments for diabetic neuropathy -- which occurs in about half of all type 2 diabetes patients -- only treat the pain, and do not treat the underlying cause of that pain.
An earlier observational study by Crane and Sample (J Nutr Med 1994; 4: 431-439) of 21 type 2 diabetics with nerve pain showed that being on a low-fat, high-fiber vegan diet for a month brought complete pain relief to 81% of participants, who lost about 11 pounds on average.The majority of these patients were also able to reduce their diabetes medications and blood pressure medications.
To see whether similar benefits would hold in a randomized controlled trial, Bunner and Trapp conducted the DINE study (Dietary Intervention for chronic diabetic NEuropathy pain) in 15 patients with type 2 diabetes and neuropathy, who had a mean age of 57. About half were female and half had a college education or higher.
Patients were randomized to either a low-fat, high-fiber, plant-based diet with B12 supplementation or to B12 supplementation alone. Bunner noted that diabetic patients, especially those on metformin, tend to be deficient in B12.
Those on the diet could only eat plant-based foods, and they had to limit fatty foods such as oils and nuts to 20 to 30 grams per day. They were also told to get at least 40 grams of fiber per day, and to choose foods that had a low glycemic index.
Bunner added that there were no portion limits since high-fiber foods are low in calories.Diet intervention patients also went to 20 weekly nutrition classes that involved nutrition education, social support, cooking demonstrations, and food product sampling.
With good adherence (five of seven diet patients were fully adherent), those on the diet had significantly greater improvements in McGill Pain Questionnaire scores than those on B12 alone (P=0.04), Bunner said.
They also had significantly greater reductions in body mass index (BMI) compared with controls (P=0.01).
Many other parameters were also improved with the diet compared with supplementation alone, and while the changes were significantly different from baseline, they were not significantly greater than those in the B12 group.
Those included cholesterol lowering, which was greater in the diet group but was confounded by the fact that many in that group came off lipid medications, while those in the B12 group were put on more lipid drugs, so the graphs were artificially lowered, Bunner said.
They also had significant improvements in HbA1c that didn't differ at the end of the study, possibly because of similar medication changes, she said.
Those on the vegan diet also had significant improvements in neuropathy symptom scores (NTSS-6) not seen in the control group, along with similar changes for quality-of-life scores, but the differences weren't significant at the end of the trial, possibly because of the small number of patients or because of the effect of participating in a study on the control group, Bunner said.
Still, the researchers concluded that the study demonstrates the potential of a dietary intervention for treating diabetic neuropathy pain. They plan to follow patients through 1 year and report longer-term effects.
Trapp added that she doesn't use the word "vegan" to describe the diet to patients because it's a loaded word: "some people don't like it. It's an immediate turn-off." Instead, she calls it a "plant-based" diet, and patients appear to be more open to it.


Tomado de: medpagetoday.com
Referencia: American Association of Diabetes Educators.  Bunner A, Trapp C "A dietary intervention for chronic diabetic neuropathy pain" AADE 2014.

lunes, 26 de mayo de 2014

Chromium supplementation cannot prevent diabetes

Around one quarter of the US population suffers from impaired fasting glucose, a preliminary stage of type 2 diabetes. Earlier studies have indicated that chromium supplements may have a positive effect and prevent the onset of diabetes. However, a study published in "Biological Trace Element Research" now suggests that this may not be the case.
In a meta-analysis, a researcher at the University of Miami analysed studies from the past 30 years on this topic using an improved statistical method. 16 studies published from 1985 to 2012 in which participants aged 36 to 67 years received different doses of chromium were analysed. The supplements included chromium chloride, chromium picolinate, chromium nicotinate, chromium dinicocysteinate and chromium yeast.
The analysis showed that administering chromium did not reduce the fasting glucose levels in diabetics or non-diabetics. "Some previous research reported that chromium supplements lower the levels of fasting glucose," said study author Christopher Bailey. "However, the effect may have been exaggerated or mistaken for the effects of other concurrent treatments, such as exercise training." The researcher also emphasised that previous studies had used other statistical methods that may have led to differing results.
"Although chromium supplementation doesn't lower fasting blood sugar, there may be other beneficial effects on the body that require more research," says Bailey. "Fasting blood sugar is only one aspect of human health.
Tomado de Univadis.com
Biological Trace Element Research

miércoles, 26 de marzo de 2014

Oxygen levels show varying effects on test results of SMBG

In the self-monitoring of blood glucose for patients with diabetes, the extent of partial pressure of oxygen’s influence on blood glucose measurements appears to differ among glucose oxidase systems, according to recent findings.
In the study, researchers obtained blood samples from 16 participants, selected regardless of diabetes status or diabetes type. The study population consisted of eight women and eight men (mean age, 52 years). Three of the patients had type 1 diabetes, four had type 2 diabetes and nine did not have diabetes.
The blood samples were analyzed using five electrochemical glucose oxidase systems and one electrochemical glucose dehydrogenase system. The blood samples were modified to various different partial pressure of oxygen (pO2) levels to analyze the effect of different pO2 levels on blood glucose test results. Portions of each sample were modified to three pO2 levels: ≤45 mm Hg, roughly 70 mm Hg and ≥150 mmHg. Each system was used to take five successive measurements on each sample, using the same test strip lot.
The pO2 of the blood samples was ascertained immediately before and after measurement with the SMBG systems to ensure blood glucose consistency in the samples.
Descriptive statistics were utilized to evaluate the effects of pO2 levels on systems’ measurement results. The investigators calculated the relative differences between the mean blood glucose levels at a pO2 value of roughly 70 mm Hg, which was considered comparable to pO2 levels in capillary blood samples. Mean blood glucose levels for the other pO2 level categories also were calculated.
The researchers found that the glucose oxidase systems demonstrated mean relative variations between 11.8% and 44.5% at pO2 values ≤45 mm Hg and between –14.6% and –21.2% at pO2 values ≥150 mm Hg. The glucose dehydrogenase system showed a mean relative difference of –0.3% at pO2levels ≤45 mm Hg and –0.2% at pO2 levels ≥150 mm Hg.
According to the researchers, these discrepancies in oxygen-sensitive glucose oxidase systems, particularly at decreased pO2 levels, may warrant updates in consumer transparency.
“To ensure an adequate use of oxygen-sensitive systems in daily life conditions of patients with diabetes, the pO2 range in which the systems operate well should be investigated further, and should be provided in the product information,” the researchers wrote.
Tomado de: healio.com

Schmid C. Diabetes Technol Ther. 2014;doi:10.1089/dia.2013.0184.

lunes, 27 de enero de 2014

Two More Levels to Check for Diabetes Risk?

Fructosamine and glycated albumin levels could help predict risk of diabetes and microvascular complications, particularly when glycated hemoglobin (HbA1c) levels aren't reliable, researchers found.
Having levels above the 95th percentile of each measurement was associated with an increased risk of diabetes, and both tests were predictive of retinopathy and kidney disease,Elizabeth Selvin, PhD, of Johns Hopkins, and colleagues reported online in the Lancet Diabetes & Endocrinology.
In statistical analyses, however, HbA1c maintained the best predictive tool for development of diabetes, they noted.
HbA1c is the standard for monitoring glucose control and for diagnosing diabetes, but it may not be as accurate in all settings, such as anemia, recent transfusion, pregnancy, and kidney disease.
Fructosamine and glycated albumin could serve as alternative markers of short-term glycemic control (about 2 to 4 weeks) or could add complementary prognostic information to HbA1c, the researchers said.
The fructosamine assay is available in the U.S., but has limited use because of a lack of data on long-term outcomes. The glycated albumin panel is used in Japan, but isn't common in the U.S.
To assess the performance of fructosamine and glycated albumin for identifying people at risk of diabetes or other complications, Selvin and colleagues measured levels in blood samples from 11,348 patients without diabetes and 958 patients with the disease who participated in the Atherosclerosis Risk in Communities (ARIC) study.
They found that baseline fructosamine and glycated albumin levels were strongly associated with risk of diabetes, even after adjustment in multivariate analyses. For instance, fructosamine values above 95th percentile (above 264 mcmol/L) were significantly associated with diabetes (HR 2.61, 95% CI), as were glycated albumin values above the 95th (greater than 15.2%) percentile (HR 3.27).
Both measures were also significantly associated with increased risks of retinopathy and chronic kidney disease, they reported.
However, associations between HbA1c and incident diabetes were stronger than those for fructosamine or glycated albumin, Selvin and colleagues noted. And in C-statistic analyses, HbA1c outperformed both fructosamine and glycated albumin for prediction of incident diabetes (0.759 versus 0.706 and 0.703, respectively).
Still, they concluded that their findings "suggest that fructosamine and glycated albumin can be used to predict diabetes, chronic kidney disease, and retinopathy in the community, [can] add complementary information to HbA1c, and ... might be particularly useful in settings where HbA1c testing or interpretation is problematic."
Robert Cohen, MD, of the University of Cincinnati, and William Herman, MD, of the University of Michigan in Ann Arbor, wrote in an accompanying editorial that all three tests seem to work well, but it "remains to be seen how well they perform in individuals, especially for the diagnosis of diabetes."
"Although all three measures might work well for most patients, it will not always be obvious for whom these indirect measures of average glycemia do not work," they wrote.
In the meantime, they said, clinicians should "use multiple sources of information to asses glycemia and maintain a high index of suspicion when an indirect measure does not seem correct."

Tomado de: MedPage Today
Kristina Fiore
Selvin E, et al "Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications" Lancet Diabetes & Endocrinol 2014; DOI: 10.1016/S2213-8587(13)70199-2.

jueves, 23 de enero de 2014

Intensive lifestyle interventions benefit patients with type 2 diabetes

Lifestyle interventions can have a number of positive effects in the management of type 2 diabetes.
It has been well documented in two landmark clinical trials on the prevention of diabetes that dietary changes and regular physical activity will prevent or delay the development of diabetes in high-risk individuals.

Landmark clinical trials

The Diabetes Prevention Project (DPP), a randomized controlled trial in patients with prediabetes, showed that 7% weight loss, achieved by a lifestyle modification program, reduced the 4-year cumulative incidence of diabetes by 58% vs. a placebo group that made no formal lifestyle changes. The program incorporated individual and group counseling sessions that encouraged a low-fat diet and at least 150 minutes of exercise (brisk walking) per week.
The Finnish Diabetes Prevention Study extended the DPP by looking at the reduction in the incidence of diabetes in high-risk, middle-aged (mean age, 55 years) adults at as much as 5 years post-intervention. The intervention included personal counseling sessions aimed at moderate (5%) weight loss achieved by a low-fat, high-fiber diet and moderate exercise for about 30 minutes per day. The average weight loss at 5 years was only 4.6 lb, but resulted in a lower incidence of diabetes in this population (23%) vs. placebo (11%).
Modest reductions in weight using a combination of dietary modifications and exercise resulted in significant reductions in the incidence of diabetes in high-risk individuals.

Look AHEAD

A more recent analysis of the Action for Health in Diabetes (Look AHEAD) study by Gregg and colleagues examined the association of a long-term intensive weight-loss intervention with the frequency of remission of type 2 diabetes. This was a randomized controlled trial involving more than 4,500 participants followed for 4 years. All participants had type 2 diabetes and a BMI of at least 25 at the beginning of the study. They were randomly assigned to intensive lifestyle intervention or a standard lifestyle intervention.
The intensive intervention involved weekly counseling for the first 6 months, then three sessions per month for 6 months, followed by two sessions per month for remainder of study. The primary aim of the intensive group was a reduction in total caloric intake to 1,200 kcal/day to 1,800 kcal/day, along with 175 minutes/week of exercise.
The standard group received three counseling sessions per year focusing on diet, exercise and social support. The results showed that the intensive intervention group lost significantly more weight and had greater fitness increases. The intensive group also was more likely to achieve remission of their diabetes vs. the control group (7.3% vs. 2%, respectively). It should be noted that more patients achieved partial remission than complete remission. This lends some support to more intensive lifestyle interventions than what is commonly done for many patients with type 2 diabetes. 
Tomado de: Endocrine Today, December 2013 .    James R. Taylor, PharmD, CDE

sábado, 25 de mayo de 2013

Pregnancy Issues Now, Diabetes Later?

Gestational diabetes and preeclampsia during pregnancy increase risk of diabetes later

                Both pre-eclampsia and gestational diabetes are serious pregnancy complications that require medical attention. However, they might be signs of later health issues to watch for as well.
A recent study found that developing diabetes later on, after having children, was more likely in women who had pre-eclampsia or gestational diabetes.
                Women with either pregnancy complication were twice as likely to develop diabetes later on. However, the study did not take into account whether the women were obese, so the higher risk of later diabetes could be related to the women's weight.
                The study, led by Denice S. Feig, an associate professor of medicine and obstetrics & gynecology at the University of Toronto Department of Medicine in Canada, looked at links between certain pregnancy complications and later development of diabetes.
                Women who have pre-eclampsia, gestational hypertension and/or gestational diabetes are more likely to have insulin resistance while they are pregnant.
Insulin resistance means that the body does not respond to insulin as it should. Insulin is a hormone that helps metabolize (process) carbohydrates like sugar in your body.
                Pre-eclampsia is a pregnancy complication in which a woman has high blood pressure and protein in her urine. The only treatment is to deliver the baby. Gestational hypertension is high blood pressure without protein in the urine.
                Gestational diabetes means that a woman develops diabetes while she is pregnant even though she did not have a history of diabetes before pregnancy. For most women, the diabetes goes away after delivering her baby.
                The researchers wanted to know if the insulin resistance that can accompany pre-eclampsia or gestational diabetes might increase a woman's risk for developing non-gestational diabetes later.
                A little over one million women (a total of 1,010,068) who delivered babies in Ontario between April 1994 and March 2008 were categorized based on whether they had one or more of these conditions or neither.
                A total of 22,933 women had pre-eclampsia only while 27,605 had gestational hypertension only and 30,852 had gestational diabetes only. A total of 1,476 women had both gestational diabetes and pre-eclampsia, and 2,100 women had gestational diabetes and gestational hypertension. The remaining 925,102 women did not have any of these conditions.
                The researchers then checked to see how many of the women developed diabetes after having delivered their babies up through March 2011.
                The findings revealed that women with pre-eclampsia or gestational diabetes were more likely to develop diabetes than women with neither condition.
                Approximately 6.5 out of every 1,000 women per year developed diabetes if they had had pre-eclampsia. Among women who had gestational diabetes, 5.3 of every 1,000 per year developed diabetes after having their child.
                The rate of later diabetes among those who did not have gestational diabetes or pre-eclampsia was 2.8 women out of every 1,000 each year.
                Having either pre-eclampsia alone or having gestational diabetes alone were calculated to double a woman's risk of developing diabetes in the subsequent 16 years after giving birth.
One significant limitation of the study, however, is that the researchers did not have information on the women's weight, including whether they were obese.
                Obesity increases a woman's risk for pre-eclampsia and gestational diabetes, and obesity also increases a person's risk for developing diabetes.
                Therefore, it's possible that the higher risk of later diabetes that was linked to pre-eclampsia or gestational diabetes was also related to whether the women were obese.
Kurian Thott, MD, FACOG, an OBGYN at Women's Health and Surgery Center in Washington, DC, said this study was well designed, but it fell short in "looking at variables that can be linked to both pre-eclampsia and gestational diabetes, which is maternal weight, both pre-pregnancy and post-pregnancy."
                "Doctors have know for many years that there is a correlation between pre-eclampsia and gestational diabetes, but we also factored in lifestyle, body mass index and pregnancy-related [complications] as part of this diagnostic tree," Dr. Thott said. Body mass index is a ratio of a person's height to weight, used to determine if they are a healthy weight.
                "It would be interesting to see if weight gain during pregnancy or being overweight before pregnancy added to this risk," Dr. Thott said. "Knowing this would help doctors counsel women on dietary and exercise regimes before considering getting pregnant. It would also help advise them on the importance of weight loss after pregnancy with one of these complications, as it can help manage their future pregnancy."

                It's unclear whether a woman of a normal, healthy weight who had pre-eclampsia or gestational diabetes would also be more likely to develop diabetes later, based on the findings in this study

Tomado de: dailyrx.com

martes, 16 de abril de 2013

New Protein Target for Controlling Diabetes


     Researchers at the University of California, San Diego School of Medicine have identified a previously unknown biological mechanism involved in the regulation of pancreatic islet beta cells, whose role is to produce and release insulin. The discovery suggests a new therapeutic target for treating dysfunctional beta cells and type 2 diabetes, a disease affecting more than 25 million Americans.
     Writing in the April 11, 2013 issue ofCell, Jerrold M. Olefsky, MD, associate dean for scientific affairs and distinguished professor of medicine, and colleagues say a transmembrane binding protein called fractalkine, which typically mediates cell-to-cell adhesion though its receptor, CX3CR1, can also be released from cells to circulate in the blood and stimulate insulin secretion.
     "Our discovery of fractalkine's role in beta cells is novel and has never been talked about in prior literature," said Olefsky. More importantly, the research highlights fractalkine's apparently vital role in normal, healthy beta cell function. In mouse models and in cultured human islets, the researchers found administering the protein stimulated insulin secretion and improved glucose tolerance, both key factors in diabetes. In contrast, fractalkine had no effect in mice or islets when the fractalkine receptor was deleted.
     "Whether or not decreased fractalkine or impaired fractalkine signaling are causes of decreased beta cell function in diabetes is unknown," said Olefsky. "What we do know, without doubt, is that administration of fractalkine improves or restores insulin secretion in all of the mouse models we have examined, as well as in human islet cells."
      Olefsky said fractalkine or a protein analog could prove "a potential treatment to improve insulin secretion in type 2 diabetic patients. It might also improve beta cell function or beta cell health, beyond simply increasing insulin secretion, since fractalkine prevents beta cell apoptosis (cell death) and promotes the beta cell differentiation program.
"If successfully developed, this could be an important new complement to the therapeutic arsenal we use in type 2 diabetes," Olefsky continued. "It is not likely to 'cure' diabetes, but it would certainly do a good job at providing glycemic control."
Tomado de sciencedaily.com